Tier 4 — mechanistic
Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial
Basic & Clinical Pharmacology & Toxicology
2026
139(3):e70290
Bibliography
- PubMed
- PMID 42633989
- PubMed Central
- PMC13500367
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Investigator-initiated research supported by the Department of Clinical Research at Copenhagen University Hospital Amager and Hvidovre and listed research foundations/grants. The paper reports no investigator personal financial interest in fisetin.
- Competing interests
- No investigator personal financial interest in fisetin was reported. Ove Andersen disclosed patents involving the prognostic biomarker suPAR licensed to ViroGates; ViroGates was not involved in the study. Morten Baltzer Houlind disclosed an editorial-board role without involvement in manuscript handling.
Study snapshot
| Design | Single-center, investigator-initiated, triple-blind, randomized, placebo-controlled, parallel-group clinical trial protocol. |
|---|---|
| Model | Generally healthy middle-aged and older adults aged 50 years or older. |
| Sample | Planned n=120 treated participants, allocated 1:1. |
| Intervention | Fisetin 100 mg orally once daily for 7 weeks versus matched placebo. |
| Duration | 7 weeks, with in-person visits at baseline, week 3 and week 7 plus interim safety/compliance monitoring. |
| Endpoints | Primary: change in plasma suPAR; Secondary: adverse-event occurrence and severity; Inflammation and cellular-senescence biomarkers; Epigenetic age; Frailty and physical function; Cognitive function; Quality of life |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Fisetin Senolytic: Does It Clear Senescent Cells in Humans?Fisetin is clearly senolytic in some experimental cell systems and strongly senotherapeutic in animals, but controlled proof of systemic senescent-cell clearance in...Read analysis
- Fisetin Benefits: What the Evidence Actually ShowsFisetin has strong preclinical evidence as a senotherapeutic, but human findings remain early and mixed. This evidence review separates randomized trials, human...Read analysis
- How and When to Take FisetinHuman fisetin studies use multiple schedules, and neither a high-fat meal nor morning dosing has been proved superior. This guide separates published...Read analysis
- Fisetin Dosage: What Human Studies Actually UseThere is no single established fisetin dose. Human studies have used 100 mg/day, 200–800 mg/day, 2 mg/kg intermittent dosing, ~20 mg/kg senolytic...Read analysis
- Fisetin: A Clinician's Guide to Evidence, Dose & SafetyFisetin is a plant flavonol with senolytic activity in selected cell and animal models. Human research now spans continuous low-dose regimens, intermittent...Read analysis
- Fisetin Pulse Dosing: What Human Trials Actually UseThere is no single Mayo Clinic fisetin protocol. Human trials use one-, two- and three-day pulses, with repeat intervals ranging from one...Read analysis
- Fisetin for Inflammation and Joint Pain: The Evidence (2026)Fisetin has broad preclinical anti-inflammatory activity, but human evidence is mixed. Small trials report selected biomarker changes, while the completed knee-osteoarthritis trial...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
